December 15th, 2015

Company Update: Biogen Idec Inc (NASDAQ:BIIB) – U.S. FDA approves Biogen’s hemophilia B drug Alprolix

[Reuters] – Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday. Hemophilia B is a rare, inherited disorder in . . . → Read More: Company Update: Biogen Idec Inc (NASDAQ:BIIB) – U.S. FDA approves Biogen’s hemophilia B drug Alprolix Similar Articles: Celgene Corporation (NASDAQ:CELG) – U.S. FDA approves Celgene drug for psoriatic arthritis Bristol-Myers Squibb Company (NYSE:BMY) | FDA approves Bristol-Myers drug for rare body fat disorder Stock Update: Biogen Idec Inc. (NASDAQ:BIIB) – December 27th Options Now Available For Biogen Idec (BIIB)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.